Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castaño-Bonilla T, Barragán E, Sargas C, Sanz A, Algarra L, Herrera-Puente P, García-Boyero R, Barrios M, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Serrano-López J, Martínez-López J, Sayas-Lloris MJ, Olave MT, Riaza-Grau R, Castillo TB, Larrayoz MJ, Amigo R, Jiménez-Velasco A, Sánchez J, Ayala R, Blas C, Lainez D, Serrano-López J, Sanz MA, Alonso-Domínguez JM, Montesinos P. Castaño-Bonilla T, et al. Among authors: olave mt. Dis Markers. 2022 Aug 23;2022:3132941. doi: 10.1155/2022/3132941. eCollection 2022. Dis Markers. 2022. PMID: 36051360 Free PMC article.
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T, Alonso-Dominguez JM, Barragán E, Rodríguez-Veiga R, Sargas C, Gil C, Chillón C, Vidriales MB, García R, Martínez-López J, Ayala R, Larrayoz MJ, Anguita E, Cuello R, Cantalapiedra A, Carrillo E, Soria-Saldise E, Labrador J, Recio I, Algarra L, Rodríguez-Medina C, Bilbao-Syeiro C, López-López JA, Serrano J, De Cabo E, Sayas MJ, Olave MT, Sánchez-García J, Mateos M, Blas C, López-Lorenzo JL, Lainez-Gonzalez D, Serrano J, Martínez-Cuadrón D, Sanz MA, Montesinos P. Castaño-Bonilla T, et al. Among authors: olave mt. Sci Rep. 2021 Oct 20;11(1):20745. doi: 10.1038/s41598-021-00050-x. Sci Rep. 2021. PMID: 34671057 Free PMC article.
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, López-Lorenzo JL, Gil C, Vidriales B, Falantes JF, Serrano A, Labrador J, Sayas MJ, Foncillas MÁ, Amador Barciela ML, Olave MT, Colorado M, Gascón A, Fernández MÁ, Simiele A, Pérez-Encinas MM, Rodríguez-Veiga R, García O, Martínez-López J, Barragán E, Paiva B, Sanz MÁ, Montesinos P; PETHEMA Group. Vives S, et al. Among authors: olave mt. Cancer. 2021 Jun 15;127(12):2003-2014. doi: 10.1002/cncr.33403. Epub 2021 Feb 24. Cancer. 2021. PMID: 33626197 Free article. Clinical Trial.
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Ocio EM, et al. Among authors: olave mt. Haematologica. 2015 Oct;100(10):1294-300. doi: 10.3324/haematol.2015.129577. Epub 2015 Jul 9. Haematologica. 2015. PMID: 26160880 Free PMC article. Clinical Trial.
Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A; Spanish Lymphoma Group (GELTAMO). Peñalver FJ, et al. Among authors: olave mt. Haematologica. 2017 Feb;102(2):235-245. doi: 10.3324/haematol.2016.149120. Epub 2016 Oct 20. Haematologica. 2017. PMID: 27846613 Free PMC article.
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
López-Díaz de Cerio A, García-Muñoz R, Pena E, Panizo Á, Feliu J, Giraldo P, Rodríguez-Calvillo M, Martínez-Calle N, Grande C, Olave MT, Andrade-Campos M, Bandrés E, Núñez-Córdoba JM, Inogés S, Panizo C. López-Díaz de Cerio A, et al. Among authors: olave mt. Br J Haematol. 2020 Jun;189(6):1064-1073. doi: 10.1111/bjh.16474. Epub 2020 Mar 4. Br J Haematol. 2020. PMID: 32130737 Free article. Clinical Trial.
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV. Peñalver FJ, et al. Among authors: olave mt. Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9. Eur J Haematol. 2016. PMID: 26179864
21 results